For TriReme, what is the ratio of revenue generated from APAC in comparison to global revenue?

Dr Konstantino: The revenue from APAC region is still small but once we get approval in both Japan and China, we believe it will be in the range of 30 percent growth. In view of the fast growth of the China market, it can and will go beyond that.

How do you see the demand for innovative devices for complex vascular disease in Asia? What is the trend in vascular device market?

Dr Konstantino: The Asian market is growing fast for a few reasons. Vascular disease is prevalent in Asia (more than in the West) but it is undertreated. In recent years, due to the economic growth, more people in China, Thailand and other Asian countries have access to healthcare. We expect that this market segment will grow very fast and will attract more innovation to Asia. In vascular interventions, the trend is of moving away from permanent implants with the use of sophisticated drug device combinations that can treat the problem without leaving anything behind.

TriReme was formed in late 2005 as a bifurcation stent company. Our main advantage was our unique, torque-able delivery system. In 2009, we decided to focus our strategy on this aspect and leveraged our knowledge to a broad range of balloon catheters. The balloon catheters market had very little innovation in the past 10 years and the clinical need is significant. Today, we have four products that are approved in the US market, and we have started their commercialization and sales. We are developing drug-device combinations and believe that drug eluting balloons, especially our drug eluting "Chocolate", will benefit patients greatly by reducing the need for permanent implants.

What is your strategy to penetrate into the Asian market?